search
Back to results

NanOss Bioactive With Autograft and Bone Marrow Aspirate in the Posterolateral Spine

Primary Purpose

Lumbar Spinal Stenosis Secondary to Other Disease

Status
Withdrawn
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
nanOSS
Autograft
Sponsored by
Pioneer Surgical Technology, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Lumbar Spinal Stenosis Secondary to Other Disease focused on measuring Lumbar, fusion

Eligibility Criteria

21 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Is at least 21 years of age and skeletally mature.
  2. Must have cervical disc disease (defined as neck pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies) at one level in the cervical spine between C3 to T1.
  3. Must have completed a minimum of six weeks of unsuccessful conservative, non-operative care or has the presence of progressive symptoms or signs of nerve root/spinal cord compression in the face of conservative treatment.
  4. Has pre-operative objective evidence of primary diagnosis confirmed by appropriate imaging studies (Anteroposterior/Lateral/Flexion/Extension X-rays & a recent MRI).
  5. Is willing and able to comply with all clinical investigation visits and procedures including screening treatment procedures, post-operative management, the follow-up schedule and completion of forms or questionnaires.
  6. Is able to understand and sign the patient information sheet/informed consent form.

Exclusion Criteria:

  1. Requires fusion at more than one level.
  2. Has had prior fusion at the level to be treated.
  3. Has a metabolic or systemic bone disorder.
  4. Has a disease that significantly inhibits bone healing (i.e., severe osteoporosis, osteomalacia, Paget's disease).
  5. Has a systemic or local infection (active or latent).
  6. Has acute or chronic infections in the surgical area (i.e., soft tissue infections; inflammatory, bacterial bone disorders, osteomyelitis).
  7. Chronic use of steroids, other than episodic use or inhaled corticosteroids.
  8. Has any significant general illness (i.e., HIV, active metastatic cancer of any type, uncontrolled diabetes Type I, dialysis dependent renal failure, symptomatic liver disease).
  9. Has a mental or physical condition that would limit the ability to comply with study requirements or would preclude accurate evaluation.
  10. Is immunocompromised or being treated with immunosuppressive agents (including chemotherapy or radiation treatment).
  11. Has documented allergies to hydroxyapatite or porcine collagen, PEEK, titanium, titanium alloy or tantalum.
  12. Is currently pregnant, or interested in becoming pregnant during the clinical investigation follow-up.
  13. Is a smoker.
  14. Is non-English speaking.
  15. Requires the use of a bone-growth stimulator.
  16. Is a prisoner.
  17. Is currently involved in another drug or device clinical investigation that may confound the clinical trial investigation

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Experimental

    Arm Label

    Autograft bone

    nanOss with bone marrow aspirate

    Arm Description

    Outcomes

    Primary Outcome Measures

    Fusion at 12 months postoperatively.

    Secondary Outcome Measures

    Full Information

    First Posted
    December 3, 2013
    Last Updated
    January 2, 2017
    Sponsor
    Pioneer Surgical Technology, Inc.
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02005341
    Brief Title
    NanOss Bioactive With Autograft and Bone Marrow Aspirate in the Posterolateral Spine
    Official Title
    A Prospective, Nonrandomized Study to Assess Lumbar Fusion With Instrumented Posterolateral Gutter Fusions Using NanOss Bioactive
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    January 2017
    Overall Recruitment Status
    Withdrawn
    Why Stopped
    A change in research priorities after a merger
    Study Start Date
    October 2011 (undefined)
    Primary Completion Date
    September 2014 (Anticipated)
    Study Completion Date
    September 2014 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Pioneer Surgical Technology, Inc.

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The purpose of this study is to assess lumbar fusion using nanOss Bioactive bone void filler

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Lumbar Spinal Stenosis Secondary to Other Disease
    Keywords
    Lumbar, fusion

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Autograft bone
    Arm Type
    Active Comparator
    Arm Title
    nanOss with bone marrow aspirate
    Arm Type
    Experimental
    Intervention Type
    Device
    Intervention Name(s)
    nanOSS
    Intervention Type
    Device
    Intervention Name(s)
    Autograft
    Primary Outcome Measure Information:
    Title
    Fusion at 12 months postoperatively.
    Time Frame
    12 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    21 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Is at least 21 years of age and skeletally mature. Must have cervical disc disease (defined as neck pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies) at one level in the cervical spine between C3 to T1. Must have completed a minimum of six weeks of unsuccessful conservative, non-operative care or has the presence of progressive symptoms or signs of nerve root/spinal cord compression in the face of conservative treatment. Has pre-operative objective evidence of primary diagnosis confirmed by appropriate imaging studies (Anteroposterior/Lateral/Flexion/Extension X-rays & a recent MRI). Is willing and able to comply with all clinical investigation visits and procedures including screening treatment procedures, post-operative management, the follow-up schedule and completion of forms or questionnaires. Is able to understand and sign the patient information sheet/informed consent form. Exclusion Criteria: Requires fusion at more than one level. Has had prior fusion at the level to be treated. Has a metabolic or systemic bone disorder. Has a disease that significantly inhibits bone healing (i.e., severe osteoporosis, osteomalacia, Paget's disease). Has a systemic or local infection (active or latent). Has acute or chronic infections in the surgical area (i.e., soft tissue infections; inflammatory, bacterial bone disorders, osteomyelitis). Chronic use of steroids, other than episodic use or inhaled corticosteroids. Has any significant general illness (i.e., HIV, active metastatic cancer of any type, uncontrolled diabetes Type I, dialysis dependent renal failure, symptomatic liver disease). Has a mental or physical condition that would limit the ability to comply with study requirements or would preclude accurate evaluation. Is immunocompromised or being treated with immunosuppressive agents (including chemotherapy or radiation treatment). Has documented allergies to hydroxyapatite or porcine collagen, PEEK, titanium, titanium alloy or tantalum. Is currently pregnant, or interested in becoming pregnant during the clinical investigation follow-up. Is a smoker. Is non-English speaking. Requires the use of a bone-growth stimulator. Is a prisoner. Is currently involved in another drug or device clinical investigation that may confound the clinical trial investigation

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    NanOss Bioactive With Autograft and Bone Marrow Aspirate in the Posterolateral Spine

    We'll reach out to this number within 24 hrs